A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg (DWCZP-I-1)

Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.

Study Overview

• Status: Completed
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: DWCZP; Drug: Clozaril

Detailed Description

A randomized, 2-way crossover, open, phase I study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg after a multiple-dose oral administration in schizophrenia patients.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Choongju, Korea, Republic of
    • Konkuk University Hospital
  • Iksan, Korea, Republic of
    • Wonkwang University
  • Naju, Korea, Republic of
    • Naju National Hospital
  • Seoul, Korea, Republic of, 150-896
    • The Catholic University of Korea, Yeouido St.Mary's Hospital
  • Seoul, Korea, Republic of
    • Seoul National Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult male or female within range of 20 to 60.
• Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool).
• Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time.
• One who might be pregnant must get negative result for pregnancy test (urine or blood β-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal ligation or menopause are excluded.
• One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

• One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug.
• WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml.
• Administering hypertension drug or has orthostatic hypotension.
• One who has clinical problem with kidney or liver and include following criteria: CCr < 50mL/min; BUN > 30 mg/dl; ALT 또는 AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN.
• Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc).
• Record of Granulocytopenia or Myeloproliferative disorder in the past.
• Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions.
• Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody.
• Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia.
• Record of seizure in 1 year before signing informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc).
• One who constantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period.
• Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period.
• One who cannot attend routine blood tests.
• Bone marrow malfunction.
• Mental illness, durg addicted or in coma.
• One who has any kind of circulation imperfection and patient with depressed central nervous system.
• Major kidney and heart problem(e.g. myocarditis).
• Incurable epilepsy.
• Paralytic intestinal obstruction.
• Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absorption deficiency, etc.
• Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study.
• One who had drugs that can affect on result of the study for past 10 days before the study start.
• One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form.
• Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form.
• Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc).
• One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: A Group; 1.1st Administration - DWCZP tablet 100mg Mutiple dose 2.2nd Administration - Clozaril tablet 100mg Mutiple dose	Drug: DWCZP; Multiple dose; Other Names: DWCZP Tablet 100mg; Drug: Clozaril; multiple-dose; Other Names: Clozaril Tablet 100mg
EXPERIMENTAL: B Group; 1.1st Administration - Clozaril tablet 100mg Mutiple dose 2.2nd Administration - DWCZP tablet 100mg Mutiple dose	Drug: DWCZP; Multiple dose; Other Names: DWCZP Tablet 100mg; Drug: Clozaril; multiple-dose; Other Names: Clozaril Tablet 100mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Maximum Concentration of Clozapine in Plasma	Up to 12hours

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to Reach Maximum Concentration of Clozapine in Plasma	Up to 12hours
Terminal Half Life of Clozapine in Plasma	Up to 12hours
Accumulation Rate of Clozapine in Plasma	Up tp 12hours

Collaborators and Investigators

• Sponsor: Dong Wha Pharmaceutical Co. Ltd.
• Collaborators: The Catholic University of Korea; Konkuk University Hospital; Wonkwang University; DongGuk University; Seoul National Hospital; Naju National Hospital
• Investigators: Principal Investigator: Won-Myoung Bahk, M.D., The Catholic University of Korea, Yeouido St.Mary's Hospital

Publications and helpful links

Helpful Links

• The Catholic University of Korea, Yeouido St.Mary's Hospital
• Konkuk University Hospital
• Naju National Hospital
• Seoul National Hospital
• Wonkwang University
• Dongguk University

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (ACTUAL): April 1, 2013
• Study Completion (ACTUAL): August 1, 2013

Study Registration Dates

• First Submitted: July 25, 2012
• First Submitted That Met QC Criteria: July 29, 2012
• First Posted (ESTIMATE): August 1, 2012

Study Record Updates

• Last Update Posted (ACTUAL): March 27, 2017
• Last Update Submitted That Met QC Criteria: February 22, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: Schizophrenia
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Serotonin Antagonists; GABA Agents; GABA Antagonists; Clozapine
• Other Study ID Numbers: DWCZP-I-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO